4820 Emperor Boulevard
711 articles with IQVIA
IQVIA Supports Collaborative Forum of Top Pharma Leaders to Advance the Use and Acceptance of Real World Evidence
IQVIA™ said that it is pleased to be a supporter of the Real World Evidence Leadership Forum, a group consisting of senior RWE executives from 18 major pharmaceutical companies.
IQVIA’s Orchestrated Customer Engagement Platform Selected by Zentiva to Accelerate Digital Capabilities
IQVIA™, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Zentiva, a leading player in branded generic and OTC medications in the European and CIS markets, is leveraging IQVIA’s Orchestrated Customer Engagement (OCE) platform across 12 major markets. The platform will be key to helping Z
IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, reported financial results for the quarter ended September 30, 2020.
IQVIA Joins FDA to Advance COVID-19 Understanding at Community Level through COVID Active Research Experience (CARE) Project
IQVIA™ (NYSE: IQV), in scientific partnership with the U.S. Food and Drug Administration, will provide agile analytics from IQVIA’s CARE Project COVID-19 registry to support better understanding of how people in the community are affected by exposure to the coronavirus. IQVIA’s research will show what symptoms individuals experience, the length and severity and whether any medications or
IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), will announce its third-quarter financial results before the market opens on Tuesday, October 20, 2020. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvi
IQVIA Institute for Human Data Science Study: Biosimilars Reach Inflection Point – On Track to Reduce Drug Costs by $100 Bn Over Next Five Years
Patients are seeing the benefits of biosimilars in the form of lower out-of-pocket costs, depending on their insurance plan design Recent biosimilar launches of bevacizumab, trastuzumab and rituximab are set to reach nearly 60% volume share by the end of their second year on the market, significantly higher and faster than prior biosimilars Biosimilars could reach $80 billion in aggregate sales over the next five years, including $16-36
IQVIA™ (NYSE: IQV) today announced that its electronic Clinical Outcome Assessment (eCOA) solution, an advanced-study build and execution platform that optimizes real-time, direct-from-patient data collection, has been selected as the winner of the Fierce Innovation Awards – Life Sciences Edition 2020 in the Digital Health Solutions category. The Fierce Innovation Awards is a peer-revie
IQVIA™ announced that Nancy Dreyer, chief scientific officer and senior vice president, Real World Solutions, has been awarded PharmaVOICE magazine’s Red Jacket honor after she was recognized multiple times as a PharmaVOICE 100.
Drug Prices Have Become More Affordable to Most Patients, says U.S. Medicine Spending Study from the IQVIA Institute for Human Data Science
The average amount paid out-of-pocket per prescription remains steady at $10.67, unchanged from 2018 and up only $0.33 since 2014, as high levels of generic drug use and greater use of manufacturer coupons offset higher costs
IQVIA Launches OCE Optimizer to Help Intelligently Plan HCP Engagements and Maximize Commercial Effectiveness
IQVIA™ (NYSE: IQV) today introduced OCE Optimizer , an innovative solution that empowers life sciences companies to plan and refine marketing engagements with healthcare providers (HCPs) on demand. OCE Optimizer extends IQVIA’s Orchestrated Customer Engagement solution by intelligently allocating
IQVIA Reports Second-Quarter 2020 Results and Raises Full-Year 2020 Guidance Second quarter revenue $2,521 million and Adjusted EBITDA $483 million GAAP Diluted Earnings per Share $(0.12); Adjusted Diluted Earnings per Share $1.18 R&D Solutions quarterly net book-to-bill ratio 1.64x including pass throughs and 1.60x excluding pass throughs; contracted backlog including pass throughs grew 13.5 percent year-over-year to $20.5 billion
IQVIA™ (NYSE: IQV) today announced it is joining forces with JDRF , the leading global organization funding type 1 diabetes (T1D) research, to use non-identified patient-level, real world data and analytics to address unmet n
IQVIA Collaborates with LMC Manna Research to Launch the Largest Clinical Investigation Site in Canada
IQVIA™ (NYSE: IQV) today announced its strategic alliance with LMC Manna Research, the largest network of fully owned and integrated clinical research sites in Canada, to launch IQVIA’s first Prime Site in Canada. This adds to our network of more than 980 Prime and Partner clinical sites globally, which are sites with special designation assuring pharmaceutical and biotech companies their
IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., priced an offering of €711,000,000 in aggregate principal amount of senior notes due 2028.
IQVIA Launches the First Solution to Address the Unique Business and Compliance Needs of Healthcare Professionals as Part of Its OCE Suite
IQVIA™ (NYSE: IQV) today announced the launch of HCP/O Engagement Management, the industry’s first end-to-end, orchestrated healthcare professional/organization (HCP/O) solution that enables the planning, management, contracting, and payment of HCP/Os globally. “IQVIA Technologies is excited to launch its latest offering, HCP/O Engagement Management. As part of IQVIA’s Orchestrated C
IQVIA Collaborates with Australian Medical Research Institute on COVID-19 Study to Support Frontline Healthcare Workers
Randomized, double-blind clinical study will test Hydroxychloroquine as a prophylactic treatment to prevent high-risk healthcare workers from contracting COVID-19 DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--( BUSINESS WIRE )-- IQVIA™ (NYSE: IQV) today announced that the Walter and Eliza Hall Institute of Medical Research , a leading biomedical research organization in Australia, has selected IQVIA to manage COVID SHIELD, a Phase II/III randomize
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
IQVIA Joins UK Government Collaboration to Provide Single Research Platform to Speed Development of New COVID-19 Treatments
IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry, has joined the ACCORD-2 collaboration, which will fast-track development of new treatments for COVID-19. IQVIA will provide a single research platform across the United Kingdom to facilitate multiple clinical trials regardless of sponsor.
IQVIA Reports First-Quarter 2020 Results; Issues Second-Quarter 2020 Guidance and Updates Full-Year 2020 Guidance
IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, reported financial results for the quarter ended March 31, 2020.
IQVIA Launches Broad, Open COVID-19 Registry Platform to Advance Understanding, Collaboration, and Research
IQVIA™ (NYSE: IQV), a leader in Human Data Science, today announced the launch of its COVID Active Research Experience (CARE) Project at helpstopcovid19.com . The IQVIA CARE Project is an opt-in registry available to anyone – to advance understanding of COVID-19 through shared information about disease prevalence, symptom progression, and treatment outcomes. “In this unprecedented